SAN FRANCISCO, May 27, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (OTC: MEHCQ), a leading human genetics and biotechnology company, today announced its intention to file ...

Anne Wojcicki, CEO of 23andMe, has submitted a proposal to take the genetic testing company private as its stock price continues to hover below $1. Stream Los Angeles News for free, 24/7, wherever you ...

On May 19, Regeneron agreed to acquire 23andMe for $256 million. The potential acquisition is still subject to bankruptcy court approval. At its peak, 23andMe's market value swelled to $5.8 billion.

23andMe on Tuesday announced it will voluntarily delist from the Nasdaq and de-register with the U.S. Securities and Exchange Commission, according to a release. Stream Los Angeles News for free, 24/7 ...

Sometimes a public company has a controlling shareholder who wants to take it private by buying out all of the other shareholders, and that’s always messy.1 The controlling shareholder will to some ...

23andMe has a path to a higher purchase price than the $256 million offered by biotech giant Regeneron after the genetic-testing company’s former chief executive pushed a bankruptcy court to reopen ...

SALT LAKE CITY — Regeneron Pharmaceuticals has said it will preserve the privacy of 23andMe's genetic data after it acquires the DNA testing company. 23andMe filed for bankruptcy in March, and now the ...

A U.S. bankruptcy judge has cleared 23andMe’s $305 million sale to TTAM Research, a nonprofit led by co-founder Anne Wojcicki, rejecting California’s attempt to delay the deal over privacy concerns.

The bidding competition over 23andMe may not be over. The founder of 23andMe, Anne Wojcicki, has asked a federal bankruptcy court judge to reopen an auction for the genetic testing company, saying she ...

23andMe on Tuesday announced it will voluntarily delist from the Nasdaq and de-register with the U.S. Securities and Exchange Commission, according to a release. The move comes after Regeneron ...

Have you ever wondered if an established drugmaker could do better at genetics-guided research than a consumer-focused diagnostics business? Well, we could find out. Regeneron's purchase is still ...